Selegance Pharma Pvt Ltd - Charges

Every charge - open or closed - that lenders have registered against Selegance Pharma Pvt Ltd, with the most recent activity at the top.

1982-07-29 Pune, Maharashtra Active Unlisted Active Compliant
Share
SP Selegance Pharma Pvt Ltd
Open charges
0
0.00
Closed charges
3
22.40 Lakh
Total
3
22.40 Lakh
Open vs closed
Top charge holders (by amount)
Top lenders
#LenderChargesAmount
1 Others 1 15.00 Lakh
2 The Cosmos Co-Operative Bank Ltd 1 6.50 Lakh
3 The Cosmos Cooperative Bank Ltd. 1 90,000.00
All charges (3) - latest first
Charge ID Charge holder Created Modified Satisfied Amount Status
100080687 Others 20 Jan 2017 - 05 Feb 2021 15.00 Lakh Closed
90085741 The Cosmos Co-Operative Bank Ltd 31 Mar 2001 13 Feb 2014 07 Jan 2025 6.50 Lakh Closed
90083433 The Cosmos Cooperative Bank Ltd. 26 Jun 1986 - 18 Jun 2024 90,000.00 Closed
Frequently Asked Questions - Charges & borrowings
What do "charges" mean for Selegance Pharma Pvt Ltd?
Charges are registrable security interests-typically loans or credit facilities-filed with MCA against Selegance Pharma Pvt Ltd (CIN: U52311MH1982PTC027896). They indicate assets or undertakings pledged to lenders or charge holders.
What is the difference between open and closed charges?
Open charges are active or not yet fully discharged; closed (or satisfied) charges are recorded as settled or released. Counts and amounts on this page follow the statuses shown in the charge list.
How should I read the open vs closed amounts?
Open and closed amounts summarise registrable amounts by status for quick comparison; individual rows may show charge-specific amounts, holders, and dates for verification.
Who are the "top lenders" or charge holders?
Top lenders group charge holders by bank or institution name and approximate exposure so you can see which lenders appear most prominently for Selegance Pharma Pvt Ltd.
Where can I cross-check financial or ownership context?
Pair this Charges view with the Financial and Ownership sections on this company's V1 profile for loans in financial statements and cap table context alongside MCA charge filings.